Randall J. Bateman

Research interests

Publications

• Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests

  Nature Medicine · 2024 · 10.1038/s41591-024-02869-z

• Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

  Brain · 2022 · 10.1093/brain/awac333

• Lecanemab in Early Alzheimer’s Disease

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2212948

• Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring

  Nature Medicine · 2022 · 10.1038/s41591-022-02074-w

• Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

  JAMA Neurology · 2021 · 10.1001/jamaneurol.2021.3180

• Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

  The Journal of Experimental Medicine · 2020 · 10.1084/jem.20200861

• A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0781-z

• High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

  Neurology · 2019 · https://doi.org/10.1212/wnl.0000000000008081

• Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease

  Nature Medicine · 2019 · https://doi.org/10.1038/s41591-018-0304-3

• Tau Kinetics in Neurons and the Human Central Nervous System

  Neuron · 2018 · 10.1016/j.neuron.2018.02.015

• Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study

  The Lancet Neurology · 2018 · https://doi.org/10.1016/s1474-4422(18)30028-0

• Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

  Alzheimer s & Dementia · 2017 · 10.1016/j.jalz.2017.06.2266

• White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network

  Annals of Neurology · 2016 · 10.1002/ana.24647

• Alzheimer's disease

  Nature Reviews Disease Primers · 2015 · 10.1038/nrdp.2015.56

• Symptom onset in autosomal dominant Alzheimer disease

  Neurology · 2014 · 10.1212/wnl.0000000000000596

• Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease

  Science Translational Medicine · 2014 · 10.1126/scitranslmed.3007901

• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

  The Lancet Neurology · 2014 · 10.1016/s1474-4422(14)70090-0

• Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease

  Proceedings of the National Academy of Sciences · 2013 · 10.1073/pnas.1317918110

• Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1202753

• Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer’s Disease Pathology

  Science Translational Medicine · 2012 · 10.1126/scitranslmed.3004291

• Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance

  Science Translational Medicine · 2011 · 10.1126/scitranslmed.3002156

• Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

  Alzheimer s Research & Therapy · 2010 · 10.1186/alzrt59

• Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

  Science · 2010 · 10.1126/science.1197623

• Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle

  Science · 2009 · 10.1126/science.1180962

• Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

  Nature Medicine · 2006 · 10.1038/nm1438

Current projects

No projects listed.